Referências

1. Aguiar A.S., Moreira E.L., Hoeller A.A., Oliveira P.A., Cordova F.M., Glaser V., Walz R., Cunha R.A., Leal R.B., Latini A., Prediger R.D., Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice, Neuroscience, 243, pp. 46-53, (2013)
2. Allen N.E., Moloney N., Van Vliet V., Canning C.G., The rationale for exercise in the management of pain in Parkinson's disease, Journal of Parkinson's Disease, 5, pp. 229-239, (2015)
3. Binda K.H., Lillethorup T.P., Real C.C., Baerentzen S.L., Nielsen M.N., Orlowski D., Brooks D.J., Chacur M., Landau A.M., Exercise protects synaptic density in a rat model of Parkinson's disease, Experimental Neurology, 342, (2021)
4. Binda K.H., Real C.C., Ferreira A.F.F., Britto L.R., Chacur M., Antinociceptive effects of treadmill exercise in a rat model of Parkinson's disease: The role of cannabinoid and opioid receptors, Brain Research, 146521, (2020)
5. Blanchet P.J., Brefel-Courbon C., Chronic pain and pain processing in Parkinson's disease, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 87, pp. 200-206, (2018)
6. Blandini F., Nappi G., Tassorelli C., Martignoni E., Functional changes of the basal ganglia circuitry in Parkinson's disease, Progress in Neurobiology, 62, pp. 63-88, (2000)
7. Braak H., Del Tredici K., Rub U., De Vos R.A., Jansen Steur E.N., Braak E., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiology of Aging, 24, pp. 197-211, (2003)
8. Brejchova J., Holan V., Svoboda P., Expression of opioid receptors in cells of the immune system, International Journal of Molecular Sciences, 22, (2020)
9. Broen M.P., Braaksma M.M., Patijn J., Weber W.E., Prevalence of pain in Parkinson's disease: A systematic review using the modified QUADAS tool, Movement Disorders, 27, pp. 480-484, (2012)
10. Chung Y.C., Shin W.H., Baek J.Y., Cho E.J., Baik H.H., Kim S.R., Won S.Y., Jin B.K., CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease, Experimental & Molecular Medicine, 48, (2016)
11. Cristino L., Bisogno T., Di Marzo V., Cannabinoids and the expanded endocannabinoid system in neurological disorders, Nature Reviews. Neurology, 16, pp. 9-29, (2020)
12. Cury R.G., Galhardoni R., Fonoff E.T., Perez Lloret S., Dos Santos Ghilardi M.G., Barbosa E.R., Teixeira M.J., Ciampi De Andrade D., Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms, European Journal of Pain (London, England), 20, pp. 151-165, (2016)
13. de Melo Reis R.A., Isaac A.R., Freitas H.R., De Almeida M.M., Schuck P.F., Ferreira G.C., Andrade-Da-Costa B., Trevenzoli I.H., Quality of life and a surveillant endocannabinoid system, Frontiers in Neuroscience, 15, (2021)
14. de Oliveira M.N.S.L.R., Da Silva Fernandes M.J., Scorza F.A., Persike D.S., Scorza C.A., Da Ponte J.B., De Albuquerque M., Cavalheiro E.A.O., Arida R.M., Acute and chronic exercise modulates the expression of Mor opioid receptors in the hippocampal formation of rats, Brain Research Bulletin, 83, pp. 278-283, (2010)
15. De Petrocellis L., Cascio M.G., Di Marzo V., The endocannabinoid system: A general view and latest additions, British Journal of Pharmacology, 141, pp. 765-774, (2004)
16. Delay-Goyet P., Zajac J.M., Javoy-Agid F., Agid Y., Roques B.P., Regional distribution of mu, delta and kappa opioid receptors in human brains from controls and parkinsonian subjects, Brain Research, 414, pp. 8-14, (1987)
17. Deumens R., Blokland A., Prickaerts J., Modeling Parkinson's disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway, Experimental Neurology, 175, pp. 303-317, (2002)
18. Di Chiara G., Imperato A., Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats, The Journal of Pharmacology and Experimental Therapeutics, 244, pp. 1067-1080, (1988)
19. Dinas P.C., Koutedakis Y., Flouris A.D., Effects of exercise and physical activity on depression, Irish Journal of Medical Science, 180, pp. 319-325, (2011)
20. Dutra M.R.F., Jaeger M., Ilha J., Kalil-Gaspar P.I., Marcuzzo S., Achaval M., Exercise improves motor deficits and alters striatal GFAP expression in a 6-OHDA-induced rat model of Parkinson's disease, Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 33, pp. 1137-1144, (2012)
21. Engelender S., Isacson O., The threshold theory for Parkinson's disease, Trends in Neurosciences, 40, pp. 4-14, (2017)
22. Ferreira A.F.F., Binda K.H., Real C.C., The effects of treadmill exercise in animal models of Parkinson's disease: A systematic review, Neuroscience and Biobehavioral Reviews, 131, pp. 1056-1075, (2021)
23. Fricker L.D., Margolis E.B., Gomes I., Devi L.A., Five decades of research on opioid peptides: Current knowledge and unanswered questions, Molecular Pharmacology, 98, pp. 96-108, (2020)
24. Galdino G., Romero T.R.L., Silva J.F.P., Aguiar D.C., De Paula A.M., Cruz J.S., Parrella C., Piscitelli F., Duarte I.D., Di Marzo V., Perez A.C., The endocannabinoid system mediates aerobic exercise-induced antinociception in rats, Neuropharmacology, 77, pp. 313-324, (2014)
25. Gomez-Galvez Y., Palomo-Garo C., Fernandez-Ruiz J., Garcia C., Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 64, pp. 200-208, (2016)
26. Hagell P., McKenna S.P., International use of health status questionnaires in Parkinson's disease: Translation is not enough, Parkinsonism & Related Disorders, 10, pp. 89-92, (2003)
27. Hanrieder J., Ljungdahl A., Falth M., Mammo S.E., Bergquist J., Andersson M., L-DOPA-induced dyskinesia is associated with regional increase of striatal dynorphin peptides as elucidated by imaging mass spectrometry, Molecular & Cellular Proteomics, 10, (2011)
28. Hoffmann P., Terenius L., Cerebrospinal fluid immunoreactive beta-endorphin concentration is increased by voluntary exercise in the spontaneously hypertensive rat, Regulatory Peptides, 28, pp. 233-239, (1990)
29. Katona I., Freund T.F., Endocannabinoid signaling as a synaptic circuit breaker in neurological disease, Nature Medicine, 14, pp. 923-930, (2008)
30. Klann E.M., Dissanayake U., Gurrala A., Farrer M., Shukla A.W., Ramirez-Zamora A., Mai V., Vedam-Mai V., The gut-brain axis and its relation to Parkinson's disease: A review, Frontiers in Aging Neuroscience, 13, (2021)
31. Larson E.B., Wang L., Bowen J.D., McCormick W.C., Teri L., Crane P., Kukull W., Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older, Annals of Internal Medicine, 144, pp. 73-81, (2006)
32. Lesnik S., Bertalan E., Bren U., Bondar A.N., Opioid receptors and protonation-coupled binding of opioid drugs, International Journal of Molecular Sciences, 22, (2021)
33. Li Y., Chen Y., Jiang L., Zhang J., Tong X., Chen D., Le W., Intestinal inflammation and Parkinson's disease, Aging and Disease, 12, pp. 2052-2068, (2021)
34. Lima L.V., Abner T.S.S., Sluka K.A., Does exercise increase or decrease pain? Central mechanisms underlying these two phenomena, The Journal of Physiology, 595, pp. 4141-4150, (2017)
35. Ljungdahl A., Hanrieder J., Falth M., Bergquist J., Andersson M., Imaging mass spectrometry reveals elevated nigral levels of dynorphin neuropeptides in L-DOPA-induced dyskinesia in rat model of Parkinson's disease, PLoS One, 6, (2011)
36. Mechoulam R., Gaoni Y., A total synthesis of DL-delta-1-tetrahydrocannabinol, the active constituent of hashish, Journal of the American Chemical Society, 87, pp. 3273-3275, (1965)
37. Morgan M.J., Franklin K.B., 6-Hydroxydopamine lesions of the ventral tegmentum abolish D-amphetamine and morphine analgesia in the formalin test but not in the tail flick test, Brain Research, 519, pp. 144-149, (1990)
38. Mylius V., Brebbermann J., Dohmann H., Engau I., Oertel W.H., Moller J.C., Pain sensitivity and clinical progression in Parkinson's disease, Movement Disorders, 26, pp. 2220-2225, (2011)
39. Navarrete F., Garcia-Gutierrez M.S., Aracil-Fernandez A., Lanciego J.L., Manzanares J., Cannabinoid Cb1 and CB2 receptors, and monoacylglycerol lipase gene expression alterations in the basal ganglia of patients with Parkinson's disease, Neurotherapeutics, 15, pp. 459-469, (2018)
40. Piccini P., Weeks R.A., Brooks D.J., Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias, Annals of Neurology, 42, pp. 720-726, (1997)
41. Pizzolato K., Thacker D., Toro-Pagan N.D., Hanna A., Turgeon J., Matos A., Amin N., Michaud V., Cannabis dopaminergic effects induce hallucinations in a patient with Parkinson's disease, Medicina (Kaunas, Lithuania), 57, (2021)
42. Qureshi A.R., Jamal M.K., Rahman E., Paul D.A., Oghli Y.S., Mulaffer M.T., Qureshi D., Danish M.A., Rana A.Q., Non-pharmacological therapies for pain management in Parkinson's disease: A systematic review, Acta Neurologica Scandinavica, 144, pp. 115-131, (2021)
43. Rana A.Q., Qureshi A.R.M., Rahman N., Mohammed A., Sarfraz Z., Rana R., Disability from pain directly correlated with depression in Parkinson's disease, Clinical Neurology and Neurosurgery, 160, pp. 1-4, (2017)
44. Rodrigues de Paula F.T., Teixeira-Salmela L.F., Coelho De Morais Faria C.D., Rocha De Brito P.C., Cardoso F., Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson's disease, Movement Disorders: Official Journal of the Movement Disorder Society, 21, pp. 1073-1077, (2006)
45. Rosarion C.L., Exercise therapy for a patient with Parkinson disease and back pain: A case report, Journal of Chiropractic Medicine, 17, pp. 72-74, (2018)
46. Santos F.M., Grecco L.H., Pereira M.G., Oliveira M.E., Rocha P.A., Silva J.T., Martins D.O., Miyabara E.H., Chacur M., The neural mobilization technique modulates the expression of endogenous opioids in the periaqueductal gray and improves muscle strength and mobility in rats with neuropathic pain, Behavioral and Brain Functions, 10, (2014)
47. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T., CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury, Neuropharmacology, 39, pp. 777-787, (2000)
48. Sharkey K.A., Wiley J.W., The role of the endocannabinoid system in the brain-gut axis, Gastroenterology, 151, pp. 252-266, (2016)
49. Shokri-Kojori E., Naganawa M., Ramchandani V.A., Wong D.F., Wang G.J., Volkow N.D., Brain opioid segments and striatal patterns of dopamine release induced by naloxone and morphine, Human Brain Mapping, 43, 4, pp. 1419-1430, (2022)
50. Spanagel R., Herz A., Shippenberg T.S., Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway, Proceedings of the National Academy of Sciences of the United States of America, 89, pp. 2046-2050, (1992)
51. Stagg N.J., Mata H.P., Ibrahim M.M., Henriksen E.J., Porreca F., Vanderah T.W., Philip Malan T., Regular exercise reverses sensory hypersensitivity in a rat neuropathic pain model: Role of endogenous opioids, Anesthesiology, 114, pp. 940-948, (2011)
52. Stein C., New concepts in opioid analgesia, Expert Opinion on Investigational Drugs, 27, pp. 765-775, (2018)
53. Stein C., Zallner C., Opioids and sensory nerves, Handbook of Experimental Pharmacology, pp. 495-518, (2009)
54. Tinazzi M., Del Vesco C., Fincati E., Ottaviani S., Smania N., Moretto G., Fiaschi A., Martino D., Defazio G., Pain and motor complications in Parkinson's disease, Journal of Neurology, Neurosurgery, and Psychiatry, 77, pp. 822-825, (2006)
55. Van Laere K., Casteels C., Lunskens S., Goffin K., Grachev I.D., Bormans G., Vandenberghe W., Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo, Neurobiology of Aging, 33, (2012)
56. Vecchio L.M., Meng Y., Xhima K., Lipsman N., Hamani C., Aubert I., The neuroprotective effects of exercise: Maintaining a healthy brain throughout aging, Brain Plasticity, 4, pp. 17-52, (2018)
57. Veening J.G., Barendregt H.P., The effects of beta-endorphin: State change modification, Fluids and Barriers of the CNS, 12, (2015)
58. Watkins B.A., Endocannabinoids, exercise, pain, and a path to health with aging, Molecular Aspects of Medicine, 64, pp. 68-78, (2018)
59. Wirdefeldt K., Adami H.-O., Cole P., Trichopoulos D., Mandel J., Epidemiology and etiology of Parkinson's disease: A review of the evidence, European Journal of Epidemiology, 26, pp. S1-58, (2011)
60. Yaksh T.L., Substance P release from knee joint afferent terminals: Modulation by opioids, Brain Research, 458, pp. 319-324, (1988)
61. Zallner C., Stein C., Opioids, Handbook of Experimental Pharmacology, pp. 31-63, (2007)
62. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M., Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications, Trends in Neurosciences, 13, pp. 290-296, (1990)